Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.00
+0.2%
$15.51
$7.08
$17.49
$310.20M0.7790,589 shs39,996 shs
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$19.65
-0.9%
$17.69
$4.66
$34.05
$76.79M1.66134,027 shs467,267 shs
OpGen, Inc. stock logo
OPGN
OpGen
$2.58
$0.00
$0.00
$1K-1.77596 shs21 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$36.74
-0.8%
$37.78
$5.63
$46.58
$314.86M1.3950,943 shs19,042 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
-0.13%-0.40%+0.47%+12.98%+27.32%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
-1.93%+1.80%+17.35%+26.48%+0.10%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%0.00%0.00%-100.00%-100.00%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
+5.26%-4.19%-11.22%+24.65%+3,701,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.00
+0.2%
$15.51
$7.08
$17.49
$310.20M0.7790,589 shs39,996 shs
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$19.65
-0.9%
$17.69
$4.66
$34.05
$76.79M1.66134,027 shs467,267 shs
OpGen, Inc. stock logo
OPGN
OpGen
$2.58
$0.00
$0.00
$1K-1.77596 shs21 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$36.74
-0.8%
$37.78
$5.63
$46.58
$314.86M1.3950,943 shs19,042 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
-0.13%-0.40%+0.47%+12.98%+27.32%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
-1.93%+1.80%+17.35%+26.48%+0.10%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%0.00%0.00%-100.00%-100.00%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
+5.26%-4.19%-11.22%+24.65%+3,701,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.50
Reduce$12.00-19.33% Downside
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
3.33
Buy$55.0052.10% Upside

Current Analyst Ratings Breakdown

Latest MGEN, OPGN, AMRN, and SNWV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Northland Capmk
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Northland Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$55.00
8/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/22/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$54.00 ➝ $55.00
7/29/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$49.00
6/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSell$7.00 ➝ $12.00
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$228.61M1.35N/AN/A$23.62 per share0.63
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
$4.46M17.22N/AN/A$6.78 per share2.90
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M0.00N/AN/A($11.55) per share0.00
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M9.50N/AN/A($1.49) per share-24.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
-$41.87M-$20.09N/AN/AN/A-1,393.50%-141.66%-88.74%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/AN/A-1,140.36%N/A-287.58%11/13/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$8.25N/AN/A-97.03%N/A-135.15%N/A

Latest MGEN, OPGN, AMRN, and SNWV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million
7/30/2025Q2 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.26
2.34
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
0.20
4.23
4.23
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.43
0.31

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
N/A
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
3.30%
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
1.10%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
14.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.68 million20.00 millionOptionable
Miragen Therapeutics, Inc. stock logo
MGEN
Miragen Therapeutics
453.91 millionN/ANot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.57 million7.29 millionN/A

Recent News About These Companies

Northland Capmk Forecasts Sanuwave Health Q3 Earnings
Northland Capmk Predicts Sanuwave Health Q3 Earnings
Sanuwave (SNWV) Q2 Revenue Jumps 42%
Sanuwave Announces Q2 FY2025 Financial Results
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$15.00 +0.03 (+0.20%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Miragen Therapeutics stock logo

Miragen Therapeutics NASDAQ:MGEN

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

OpGen stock logo

OpGen NASDAQ:OPGN

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$36.74 -0.28 (-0.76%)
As of 03:33 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.